Medine.co.uk

Dolethal 200 Mg/Ml Solution For Injection


Part II

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Dolethal 200mg/ml solution for injection


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Per ml


Pentobarbital sodium 200.00 mg


Other constituents include:


Benzyl alcohol 10.40 mg

Ponceau 4R (E124) 0.01 mg


For a full list of excipients, see section 6.1


3. PHARMACEUTICAL FORM


A pink liquid solution for injection


4. CLINICAL PARTICULARS

Target species


Small animals and cattle.


4.2 Indications for use, specifying the target species


For euthanasia of small animals (mainly dogs and cats) and cattle.


4.3 Contra-indications


Not to be used in animals intended for animal consumption. Do not use for anaesthesia.


4.4 Special warnings for each target species


None


4.5 Special precautions for use

Special precautions for use in animals


Any volume administered outside the vein will reduce the efficacy of the dose.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


Wear suitable protective gloves when handling the product. Avoid accidental self-administration and self-injection.


In the case of accidental self-administration, by injection, ingestion or skin absorption, seek URGENT medical attention, advising medical service of barbiturate poisoning.


In the event of an accident the following action should be taken:


Skin-Wash immediately with water and then thoroughly with soap and water.


Eyes- Wash immediately with cold water and obtain medical attention.


Ingestion- Obtain medical attention immediately. Wash out mouth. Keep warm and rest.


Accidental self-injection- Obtain URGENT medical attention, advising medical services of barbiturate poisoning. Do not leave patient unattended.


Advice to Doctor- Maintain airways and give symptomatic and supportive treatment.


Adverse reactions (frequency and seriousness)


None


Use during pregnancy, lactation or lay


Not Applicable


Interaction with other medicinal products and other forms of interaction


The effects of the productl are increased by concomitant administration of sedatives (xylazine or acepromazine).


Amounts to be administered and administration route


0.7ml per kg bodyweight by rapid intravenous injection. The product solution is not intended for dilution with water or any other fluid.


Overdose (symptoms, emergency procedures, antidotes), if necessary

In the event of accidental administration to an animal not presented for euthanasia, measures such as artificial respiration, administration of oxygen and the use of analeptics are appropriate.


Withdrawal period(s)


Not to be used in animals intended for human consumption.


5. PHARMACOLOGICAL PROPERTIES


The active ingredient in Dolethal is pentobarbital, which is a barbiturate. Barbiturates act by depressing the central nervous system, inhibiting accumulation of calcium in nervous tissue, which leads to liberation of norepinephrine, acetylcholine, glutamate and gamma-aminobutyric acid. This leads to sedation and coma.

Barbiturates also act on cardiac and respiratory systems bringing on apnoea and cardiac arrest.


PHARMACEUTICAL PARTICULARS

List of excipients


Propylene Glycol

Water for Injections

Isopropyl alcohol


Incompatibilities


None known


Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Shelf life after opening the immediate packaging: 3 months.


Special precautions for storage


The product solution is not intended for dilution with water or any other fluid.

Protect from light.

Following withdrawal of the first dose use within 3 months. Discard any unused materials.

6.5 Nature and composition of immediate packaging

Carton containing colourless multidose glass bottles containing 100 or 250 ml non-sterile aqueous solution. Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste

materials derived from the use of such products

Any unused product must be destroyed in accordance with the Misuse of Drugs Regulations (2001). Any waste materials should be disposed of in accordance with local requirements.


MARKETING AUTHORISATION HOLDER


VĂ©toquinol UK Limited Vetoquinol House Great Slade Buckingham Industrial Park Buckingham MK18 1PA


8. MARKETING AUTHORISATION NUMBER(S)


Vm 08007/4034


9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION


02 June 1992/02 June 2007


10. DATE OF REVISION OF THE TEXT


January 2008